Wake

Therapeutics

We’re applying our discoveries in biosciences to create breakthrough
therapeutics that help humans everywhere. This is how we grow.

The Wake
Genomics Project

In partnership with the Lieber Institute for Brain Development Maltz Research Laboratories (LIBD), Wake is developing a cutting-edge genetics-based research initiative for safe administration of psychedelic-assisted psychotherapy.

The Wake Genomics Project will be a laboratory screening process integrated with a one of a kind cloud-based AI-Reference library of genetics.


Psilocybin
Clinical Trials

Fungi TypeProductionProduct DevelopmentIRB ApprovalTrial RegistrationDrug RegistrationRecruitment Begins
Fungi Based Microdose
Focus: Anxiety and Depression
Fungi Based Microdose
Focus: PTSD (Health Disparity Focused)
Fungi Based Microdose
Focus: PTSD (Health Disparity Focused)

Genomics-Based
Athletic T.B.I Study

Woke is developing a Traumatic Brain Injury study in collaboration with the University of West Indies, Lieber Institute for Brain Development and our partners. This is the first study that brings a genetics-based approach to study the effects of psilocybin on Traumatic Brain Injury. Wake is building an Athletic Council dedicated to research, recruitment and awareness on TBI and psilocybin as a therapeutic.